For people living with chronic hepatitis B, the treatment routine has long been a grind of daily pills and constant monitoring. On Thursday, scientists unveiled something very different: an experimental shot called bepirovirsen that delivered durable, remission-like results in a subset of patients, letting some stop all therapy while key viral markers stayed undetectable for months.
If regulators agree, that could mean trading years of daily medication for a finite course of injections, and sharply lowering the lifetime odds of cirrhosis and liver cancer for many patients.
The findings have dominated national coverage and scientific briefings this week. The New York Times laid out the early results and patient stories, while The Associated Press reported that roughly one in five people who received the drug met the trial definition of a functional cure, compared with none in the placebo group.
What the pivotal trials showed
The late-stage B-Well program enrolled more than 1,800 adults across 29 countries in randomized, placebo-controlled studies. Participants received weekly subcutaneous injections of bepirovirsen alongside standard nucleos(t)ide therapy.
Ionis Pharmaceuticals, which is partnering with GSK on development, said the trials hit their primary endpoint, delivering a statistically significant and clinically meaningful functional cure rate in patients who received bepirovirsen compared with those on placebo.
How bepirovirsen works and what experts said
Bepirovirsen is an antisense oligonucleotide, a type of targeted genetic medicine designed to bind hepatitis B viral RNA. By doing that, it lowers production of the surface antigen (HBsAg) and suppresses viral replication so the immune system has a better shot at clearing infected cells. Earlier clinical reports have outlined this mechanism and described the drug’s safety profile in mid-stage testing.
The New England Journal of Medicine previously reviewed phase 2 data on bepirovirsen, including its activity against the virus and signals that doctors would need to watch as the drug moved into larger trials. Experts quoted in The New York Times called the new results “remarkable” and described them as a major step forward in a disease area that has seen few curative advances in decades.
Regulatory timeline and next steps
GSK has already taken the data to regulators. The company says the U.S. Food and Drug Administration has accepted its application for priority review and set a Prescription Drug User Fee Act, or PDUFA, action date of October 26, 2026.
According to GSK, the company and Ionis plan to publish the full trial results in a peer-reviewed journal and present the complete dataset at major hepatology conferences over the spring and summer.
Limits of the data so far
For all the excitement, the trials still leave key questions on the table. Investigators note that the studies excluded people with cirrhosis, those with active HIV infection, and patients with very high baseline HBsAg levels. Some participants experienced injection-site reactions or temporary spikes in liver enzymes, side effects that will require routine monitoring if the drug reaches the market.
The biggest unknown is durability. The pivotal trials tracked patients for months after treatment stopped, and responses held up over that period, but clinicians and insurers alike want to know how long those functional cures last over the longer term. Follow-up studies are already in progress to answer that.
Why it matters for U.S. patients
Chronic hepatitis B remains a major global public health problem, with more than a quarter billion people estimated to be living with chronic infection worldwide. In the United States, estimates range from several hundred thousand to more than two million people, depending on the methodology used.
Government surveillance and advocacy organizations have long warned that chronic hepatitis B is underdiagnosed and undertreated, particularly in communities with limited access to care. A finite treatment that can deliver a functional cure could have an outsized impact, but only if testing, insurance coverage and affordability keep pace.
CDC data highlight ongoing gaps in identifying infections, and the Hepatitis B Foundation has stressed persistent shortfalls in getting patients into consistent treatment. Those structural problems will heavily influence how widely and how quickly bepirovirsen is used if it wins approval.
For now, patients and clinicians are waiting on the full peer-reviewed paper and the detailed FDA briefing documents due in the coming months. If the complete data hold up and regulators give the green light, bepirovirsen could reshape care for people with chronic hepatitis B, but eligibility criteria, long-term durability and real-world access will ultimately decide how far that change reaches.
